Bio-Rad Laboratories Class A
343 hedge funds and large institutions have $5.95B invested in Bio-Rad Laboratories Class A in 2018 Q3 according to their latest regulatory filings, with 47 funds opening new positions, 112 increasing their positions, 133 reducing their positions, and 28 closing their positions.
68% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 28
10% more capital invested
Capital invested by funds: $5.42B → $5.95B (+$521M)
5% more funds holding
Funds holding: 326 → 343 (+17)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0.64% less ownership
Funds ownership: 77.57% → 76.93% (-0.64%)
16% less repeat investments, than reductions
Existing positions increased: 112 | Existing positions reduced: 133
87% less call options, than puts
Call options by funds: $438K | Put options by funds: $3.26M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$70.4M |
| 2 |
Select Equity Group
New York
|
+$44.3M |
| 3 |
D.E. Shaw & Co
New York
|
+$33.6M |
| 4 |
BC
Bodenholm Capital
Stockholm,
Sweden
|
+$32.3M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$30.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$71.6M |
| 2 |
Millennium Management
New York
|
-$59.6M |
| 3 |
ACM
Atlanta Capital Management
Atlanta,
Georgia
|
-$44.8M |
| 4 |
SC
Samlyn Capital
New York
|
-$28.2M |
| 5 |
FWIA
Fort Washington Investment Advisors
Cincinnati,
Ohio
|
-$26.7M |
BIO Hedge Fund Activity: Q3 2018 in Review
343 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q3 2018, worth a combined $5.95B — up 9.6% from $5.42B a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new BIO positions and 28 closed out — a net gain of 19 holders — while 112 added to existing stakes and 133 trimmed.
The largest buyer was Federated Hermes, adding an estimated $70.4M. The largest seller was Renaissance Technologies, cutting an estimated $71.6M.
- 343 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q3 2018, up from 326 in Q2 2018.
- Funds reported $5.95B of Bio-Rad Laboratories Class A stock for Q3 2018, up 9.6% quarter-over-quarter.
- 47 funds opened new Bio-Rad Laboratories Class A positions in Q3 2018 and 28 closed out, a net change of +19 holders.
- The largest Bio-Rad Laboratories Class A buyer in Q3 2018 was Federated Hermes, an estimated $70.4M added.
- The largest Bio-Rad Laboratories Class A seller in Q3 2018 was Renaissance Technologies, an estimated $71.6M sold.
Based on aggregated 13F filings for Q3 2018.